MARRONE BIO INNOVATIONS INC Form 3 August 01, 2013 FORM 3 UNITED STATES SECUR Was

3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB 3235-0104 Number: January 31, 2005 Estimated average burden hours per response... 0.5

6. Individual or Joint/Group

(Print or Type Responses)

1. Name and Address of Reporting Person <u>*</u> Pitts Keith		 Date of Event Requiring Statement (Month/Day/Year) 	3. Issuer Name and Ticker or Trading Symbol MARRONE BIO INNOVATIONS INC [MBII]			
(Last)	(First)	(Middle)	08/01/2013	4. Relationship of Reporting Person(s) to Issuer	5. If Amendment, Date Original Filed(Month/Day/Year)	
C/O MARE				(Check all applicable)		

Director

(give title below) (specify below)

See Remarks

__X_ Officer

10% Owner

Other

INNOVATIONS, INC., 2121 SECOND STREET, SUITE A-107

(Street)

DAVIS, C.	AÂ 95618		·		Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person
(City)	(State)	(Zip)	Table I - Non-Deriva	ative Securit	ies Beneficially Owned
1.Title of Secur (Instr. 4)	ity		2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Reminder: Repo owned directly	-		h class of securities beneficially	SEC 1473 (7-02	2)
	inforn requii	nation contai red to respon	ond to the collection of ned in this form are not d unless the form displays a B control number.		

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security	2. Date Exercisable and	3. Title and Amount of	4.	5.	6. Nature of Indirect
(Instr. 4)	Expiration Date	Securities Underlying	Conversion	Ownership	Beneficial Ownership
	(Month/Day/Year)	Derivative Security	or Exercise	Form of	(Instr. 5)
		(Instr. 4)	Price of	Derivative	
			Derivative	Security:	

Edgar Filing: MARRONE BIO INNOVATIONS INC - Form 3

	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Security	Direct (D) or Indirect (I) (Instr. 5)	
Stock Option (Right to Buy)	(1)	07/21/2018	Common Stock	15,931	\$ 0.47	D	Â
Stock Option (Right to Buy)	(2)	01/28/2019	Common Stock	4,779	\$ 1.19	D	Â
Stock Option (Right to Buy)	(<u>3)</u>	01/11/2020	Common Stock	4,779	\$ 1.19	D	Â
Stock Option (Right to Buy)	(4)	01/11/2020	Common Stock	4,779	\$ 1.19	D	Â
Stock Option (Right to Buy)	(5)	01/24/2021	Common Stock	17,620	\$ 1.19	D	Â
Stock Option (Right to Buy)	(6)	12/15/2021	Common Stock	15,931	\$ 1.41	D	Â
Stock Option (Right to Buy)	(7)	02/20/2022	Common Stock	11,487	\$ 3.11	D	Â
Stock Option (Right to Buy)	(8)	10/18/2022	Common Stock	23,897	\$ 12.08	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships				
	Director	10% Owner	Officer	Other	
Pitts Keith C/O MARRONE BIO INNOVATIONS, INC. 2121 SECOND STREET, SUITE A-107 DAVIS, CA 95618	Â	Â	See Remarks	Â	
Signatures					
/s/ Donald J. Glidewell, Donald J. Glidewell, Attorney-in-Fact	08/01/2013				
**Signature of Reporting Person			Date		

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The option vested with respect to 1/4th of the total shares subject to the option on the first anniversary of the vesting commencement date of July 1, 2008, and 1/48th of the total shares subject to the option monthly thereafter for 36 months.
- (2) The option vested with respect to 1/4th of the total shares subject to the option on the first anniversary of the vesting commencement date of January 1, 2009, and 1/48th of the total shares subject to the option monthly thereafter for 36 months.
- (3) The option vested with respect to 1/4th of the total shares subject to the option on the first anniversary of the vesting commencement date of January 1, 2010, and 1/48th of the total shares subject to the option monthly thereafter for 36 months.
- (4) The option vested with respect to 100% of the total shares subject to the option on the vesting commencement date of January 1, 2010.

Edgar Filing: MARRONE BIO INNOVATIONS INC - Form 3

- (5) The option vested with respect to 100% of the total shares subject to the option on the vesting commencement date of January 1, 2011.
- (6) The options vest with respect to 1/60th of the total shares subject to the option one month after the vesting commencement date of November 1, 2011, and 1/60th of the total shares subject to the option monthly thereafter for 36 months.
- (7) The option vested with respect to 100% of the total shares subject to the option on the vesting commencement date of February 20, 2012.
- (8) The option vested with respect to 1/4th of the total shares subject to the option on the first anniversary of the vesting commencement date of October 18, 2012, and 1/48th of the total shares subject to the option monthly thereafter for 36 months.

Â

Remarks:

Vice President of Regulatory and Governmental Affairs

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.